Table 4. Multivariate analysis was performed to assess the predictiveness of Ki67 and DLX2 compared with PSA concentration, Gleason groups and D'Amico risk.
|
95% Confidence interval |
||||
|---|---|---|---|---|
| Variable | Significance | Hazard ratio | Lower | Upper |
|
Ki67 survival prediction | ||||
| Ki67 | 0.029 | 2.436 | 1.096 | 5.416 |
| PSA concentration | 0.290 | 1.00 | 1.000 | 1.000 |
| Gleason categories | 0.936 | 1.018 | 0.659 | 1.572 |
| D'Amico risk | 0.964 | 0.919 | 0.347 | 2.433 |
|
Ki67 metastasis prediction | ||||
| Ki67 | 0.023 | 3.296 | 1.181 | 9.196 |
| PSA concentration | 0.131 | 1.001 | 1.000 | 1.002 |
| Gleason categories | 0.146 | 1.469 | 0.874 | 2.469 |
| D'Amico risk | 0.325 | 0.600 | 0.217 | 1.660 |
|
DLX2 metastasis prediction | ||||
| DLX2 | 0.003 | 3.051 | 1.451 | 6.418 |
| PSA concentration | 0.202 | 1.002 | 0.999 | 1.004 |
| Gleason categories | 0.768 | 1.081 | 0.643 | 1.819 |
| D'Amico risk | 0.827 | 0.891 | 0.316 | 2.511 |
Abbreviation: PSA=prostate specific antigen.